These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. Buttgereit F; Palmowski A Joint Bone Spine; 2022 Jan; 89(1):105285. PubMed ID: 34601110 [TBL] [Abstract][Full Text] [Related]
65. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis. Rossi D; Cecchi I; Sciascia S; Naretto C; Alpa M; Roccatello D Clin Exp Rheumatol; 2021; 39 Suppl 129(2):125-128. PubMed ID: 33635228 [TBL] [Abstract][Full Text] [Related]
66. Vision loss in patients with giant cell arteritis treated with tocilizumab. Amsler J; Kysela I; Tappeiner C; Seitz L; Christ L; Scholz G; Stalder O; Kollert F; Reichenbach S; Villiger PM Arthritis Res Ther; 2021 Mar; 23(1):92. PubMed ID: 33752737 [TBL] [Abstract][Full Text] [Related]
67. New Therapeutic Approaches to Large-Vessel Vasculitis. Kaymakci MS; Warrington KJ; Kermani TA Annu Rev Med; 2024 Jan; 75():427-442. PubMed ID: 37683286 [TBL] [Abstract][Full Text] [Related]
68. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270 [TBL] [Abstract][Full Text] [Related]
69. [Treatment of giant cell arteritis]. Samson M; Greigert H; Ghesquière T; Bonnotte B Presse Med; 2019 Sep; 48(9):968-979. PubMed ID: 31324351 [TBL] [Abstract][Full Text] [Related]
70. Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight: "Risk profiling for GC resistance in GCA". Liozon E; Dumonteil S; Parreau S; Gondran G; Bezanahary H; Palat S; Ly KH; Fauchais AL Semin Arthritis Rheum; 2020 Dec; 50(6):1252-1261. PubMed ID: 33065420 [TBL] [Abstract][Full Text] [Related]
71. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis. Lavergne A; Dumont A; Deshayes S; Boutemy J; Maigné G; Silva NM; Nguyen A; Gallou S; Philip R; Aouba A; de Boysson H Semin Arthritis Rheum; 2023 Jun; 60():152192. PubMed ID: 36963127 [TBL] [Abstract][Full Text] [Related]
75. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy. Higashida-Konishi M; Akiyama M; Shimada T; Hama S; Oshige T; Izumi K; Oshima H; Okano Y Rheumatol Int; 2023 Mar; 43(3):545-549. PubMed ID: 36152056 [TBL] [Abstract][Full Text] [Related]
76. Need and value of targeted immunosuppressive therapy in giant cell arteritis. Sandovici M; van der Geest N; van Sleen Y; Brouwer E RMD Open; 2022 Feb; 8(1):. PubMed ID: 35149602 [TBL] [Abstract][Full Text] [Related]
77. Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia. Robinson L; Hamden M; Griggs K; Simon S; Hill C; Limaye V; Proudman S Intern Med J; 2024 Jul; 54(7):1228-1232. PubMed ID: 38953308 [TBL] [Abstract][Full Text] [Related]